Is Cetuximab an Immunotherapy?
Cetuximab is not a traditional immunotherapy—it is a targeted therapy (monoclonal antibody) that primarily works by blocking the epidermal growth factor receptor (EGFR), though it does possess immune-mediated mechanisms of action that distinguish it from purely targeted agents.
Mechanism of Action and Classification
Cetuximab is formally classified as a chimeric monoclonal antibody and EGFR antagonist 1. It binds specifically to the extracellular domain of EGFR, competitively inhibiting ligand binding and blocking downstream signaling pathways including RAS-ERK activation 1. This direct receptor blockade represents its primary mechanism—characteristic of targeted therapy rather than immunotherapy.
However, cetuximab has important immunologic properties that blur traditional classifications:
- As an IgG1 isotype antibody, cetuximab mediates antibody-dependent cell-mediated cytotoxicity (ADCC) involving natural killer (NK) cells, T-cell recruitment, and dendritic cell maturation 2, 3
- Cetuximab induces immunogenic cell death (ICD) when combined with chemotherapy, triggering endoplasmic reticulum stress and enhancing phagocytosis by dendritic cells 4
- Clinical evidence demonstrates enhanced immune cell infiltration at tumor sites, with increased CD3+, CD8+, and CD56+ cells in liver metastases of colorectal cancer patients treated with cetuximab 5, 6
Clinical Context Across Malignancies
Colorectal Cancer
In metastatic colorectal cancer, cetuximab functions primarily as a targeted therapy indicated only for RAS wild-type tumors (KRAS/NRAS wild-type) 7, 8, 9. The NCCN guidelines explicitly state that patients with KRAS or NRAS mutations should not receive cetuximab because "they have virtually no chance of benefit" 8, 9. This biomarker-driven approach is characteristic of targeted therapy, not immunotherapy.
Head and Neck Cancer
For recurrent/metastatic head and neck squamous cell carcinoma, cetuximab is described as "the first biologic agent to enter routine clinical practice" 10. The EXTREME trial demonstrated survival benefit when cetuximab was added to platinum-based chemotherapy 10. Recent guidelines now position cetuximab as an alternative to immunotherapy (pembrolizumab) in certain contexts 11.
Lung Cancer
In non-small cell lung cancer, cetuximab showed modest benefits but is not recommended outside clinical trials due to inconsistent survival benefits relative to toxicity and cost 12.
Key Distinction from True Immunotherapy
The critical distinction: While checkpoint inhibitors (pembrolizumab, nivolumab) work by releasing brakes on the immune system to enable T-cell-mediated tumor killing, cetuximab works by:
- Directly blocking EGFR signaling (targeted mechanism)
- Secondarily engaging immune effector functions through its IgG1 structure (immune-mediated mechanism)
This dual mechanism explains why cetuximab is being studied in combination with checkpoint inhibitors—the rationale being that cetuximab's ADCC activity and ICD induction can prime the tumor microenvironment for enhanced response to true immunotherapy 3, 4, 13.
Practical Clinical Implications
- Do not substitute cetuximab for checkpoint inhibitors in settings where immunotherapy is indicated
- Cetuximab requires RAS/NRAS wild-type status in colorectal cancer—this molecular requirement reflects targeted therapy principles 8, 9
- The IgG1 structure matters: Unlike panitumumab (IgG2), cetuximab's immune effector functions may provide additional benefit, particularly when combined with immunotherapy 2, 3
- Emerging role as immunotherapy partner: Cetuximab is increasingly studied in combination with checkpoint inhibitors to harness both EGFR blockade and immune activation 3, 13, 14
In summary: Cetuximab should be classified as a targeted monoclonal antibody with immune-mediated mechanisms of action, not as a traditional immunotherapy agent like checkpoint inhibitors.